Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus

Lupus

Volumn 16, Issue 12, 2007, Pages 981-986

  Avalos, Ingrid ^a   Chung, Cecilia P ^a   Oeser, Annette ^a   Milne, Ginger L ^a   Borntrager, Holly ^a   Morrow, Jason D ^a   Raggi, Paolo ^b   Solus, Joseph ^a   Stein, C Michael ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Asprin resistance; Oxidative stress; Prostacyclin; Systemic lupus erythematosus; Thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; CREATININE; PROSTACYCLIN; THROMBOXANE; THROMBOXANE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BIOSYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DRUG MECHANISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; URINARY EXCRETION;

ADULT; ASPIRIN; CYCLOOXYGENASE INHIBITORS; DRUG RESISTANCE; EPOPROSTENOL; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; THROMBOXANE A2;

EID: 37849016152     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307083313     Document Type: Article

References (27)

1. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Symthe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221-225.
2. Asanuma Y, Oeser A, Shintani AK et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407-2415.
3. Chung CP, Oeser A, Avalos I, Raggi P, Stein CM. Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 2006; 15: 562-569.
4. Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus - proposed guidelines for risk factor management. Rheumatology (Oxf) 2004; 43: 7-12.
5. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1: 1710-1713.
6. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
7. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817.
8. Rocca B, Secchiero P, Ciabattoni G et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002; 99: 7634-7639.
9. Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 1998; 79: 691-705.
10. Csiszar A, Stef G, Pacher P, Ungvari Z. Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 557-558.
11. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 2002; 105: 1620-1622.
12. Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras LO. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991; 78: 2894-2899.
13. Patrono C, Ciabattoni G, Remuzzi G et al. Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. J Clin Invest 1985; 76: 1011-1018.
14. Ferro D, Basili S, Roccaforte S et al. Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2689-2697.
15. Davi G, Falco A. Oxidant stress, inflammation and atherogenesis. Lupus 2005; 14: 760-764.
16. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
17. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983; 26: 1346-1353.
18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
19. Gladman DD, Urowitz MB, Goldsmith CH et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 809-813.
20. Morrow JD, Minton TA. Improved assay for the quantification of 11-dehydrothromboxane B2 by gas chromatography-mass spectrometry. J Chromatogr 1993; 612: 179-185.
21. Daniel VC, Minton TA, Brown NJ, Nadeau JH, Morrow JD. Simplified assay for the quantification of 2,3-dinor-6-keto-prostaglandin F1 alpha by gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl 1994; 653: 117-122.
22. Morrow JD, Roberts LJ. Mass spectrometry of prostanoids: F2-isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism. Methods Enzymol 1994; 233: 163-174.
23. Yoshida T, Ichikawa Y, Tojo T, Homma M. Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904. Lupus 1996; 5: 129-138.
24. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl): 234S-264S.
25. Morrow JD, Roberts LJ. Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods Enzymol 1999; 300: 3-12.
26. Avalos I, Chung CP, Oeser A et al. Oxidative stress in systemic lupus erythematosus: relationship to disease activity and symptoms. Lupus 2007; 16: 195-200.
27. Frelinger AL III, Furman MI, Linden MD et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113: 2888-2896.